Tsui Irena, Pan Carolyn K, Rahimy Ehsan, Schwartz Steven D
Retina Division, Jules Stein Eye Institute, University of California, Los Angeles, CA 90095, USA.
J Biomed Biotechnol. 2012;2012:354979. doi: 10.1155/2012/354979. Epub 2012 Oct 14.
Fibronectin and laminin are clinically relevant plasmin receptors in the eye. Located at the vitreoretinal interface, they are cleaved by ocriplasmin (Microplasmin, ThromboGenics, Iselin, NJ), a novel ophthalmic medication. A series of clinical trials to study ocriplasmin for the treatment of vitreoretinal diseases such as vitreomacular traction, macular hole, and exudative age-related macular degeneration are underway. The results are promising and may impact patient care.
纤连蛋白和层粘连蛋白是眼部临床上相关的纤溶酶受体。它们位于玻璃体视网膜界面，可被一种新型眼科药物ocriplasmin（Microplasmin，ThromboGenics公司，新泽西州伊塞尔林）裂解。一系列研究ocriplasmin治疗玻璃体视网膜疾病（如玻璃体黄斑牵拉、黄斑裂孔和渗出性年龄相关性黄斑变性）的临床试验正在进行中。结果很有前景，可能会影响患者护理。
